Added to YB: 2024-10-31
Pitch date: 2024-09-30
207940.KS [bullish]
Samsung Biologics Co.,Ltd.
+43.56%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally.
Market Cap
KRW 74.5T
Pitch Price
KRW 1.2M
Price Target
N/A
Dividend
N/A
EV/EBITDA
39.36
P/E
72.46
EV/Sales
17.72
Sector
Life Sciences Tools and Services
Category
growth
Show full summary:
Artisan Sustainable Emerging Markets Fund Portfolio Holding: Samsung Biologics Co.,Ltd.
207940.KS: Samsung Biologics up on 2 FDA approvals. Strong partnerships with top pharma cos. Secured large-scale manufacturing deals. Well-positioned for biopharma market growth. Korean leader gaining momentum in global market.
Read full article (1 min)